MarketCap
Facebook
X
Telegram
Mirati Therapeutics Total Assets | MRTX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Mirati Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.2 B | 1.59 B | 1.48 B | 432 M | 228 M | 157 M | 63.4 M | 128 M | 33.5 M | 64.5 M | 39.8 M | 31 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.59 B | 31 M | 454 M |
Quarterly Total Assets Mirati Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 B | 915 M | 1.03 B | 1.2 B | 1.3 B | 1.28 B | 1.42 B | 1.59 B | 1.25 B | 1.36 B | 1.38 B | 1.48 B | 620 M | 664 M | 713 M | 432 M | 471 M | 501 M | 309 M | 228 M | 248 M | 265 M | 155 M | 157 M | 82.1 M | 95 M | 111 M | 63.4 M | 79.2 M | 96 M | 113 M | 128 M | 144 M | 61.9 M | 72.2 M | 33.5 M | 41.3 M | 49.7 M | 56.3 M | 64.5 M | 18 M | 23 M | 64.5 M | 39.8 M | 39.8 M | 39.8 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.59 B | 18 M | 470 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
134 B | $ 263.04 | 0.49 % | $ 465 B |  USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 11.41 | 2.15 % | $ 3.41 B |  Canada |
 |
Фармсинтез
LIFE
|
2.05 B | - | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
160 M | $ 5.53 | 6.02 % | $ 678 M | USA |
 |
ADC Therapeutics SA
ADCT
|
323 M | $ 1.09 | 3.74 % | $ 139 M |  Schweiz |
 |
Amryt Pharma plc
AMYT
|
816 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
64.4 M | - | -14.46 % | $ 27.9 M | USA |
 |
Allakos
ALLK
|
96.6 M | - | - | $ 28.6 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | USA |
 |
Clovis Oncology
CLVS
|
473 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
146 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
165 M | - | - | $ 401 M | USA |
 |
ADMA Biologics
ADMA
|
624 M | $ 8.61 | 0.16 % | $ 2.05 B | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
38.8 M | - | -9.21 % | $ 2.55 M | USA |
|
89bio
ETNB
|
479 M | - | - | $ 1.55 B | USA |
 |
Freeline Therapeutics Holdings plc
FRLN
|
86.6 M | - | - | $ 384 M | Britain |
 |
Fusion Pharmaceuticals
FUSN
|
286 M | - | - | $ 1.41 B | Canada |
 |
Guardion Health Sciences
GHSI
|
11.9 M | - | -0.31 % | $ 3.64 M | USA |
 |
Genocea Biosciences
GNCA
|
56 M | - | -15.0 % | $ 3.04 M | USA |
 |
Gritstone Oncology
GRTS
|
178 M | - | 0.42 % | $ 213 M | USA |
 |
G1 Therapeutics
GTHX
|
122 M | - | - | $ 370 M | USA |
 |
Harpoon Therapeutics
HARP
|
73.7 M | - | - | $ 763 M | USA |
 |
Humanigen
HGEN
|
11.2 M | - | -81.12 % | $ 4.28 M | USA |
 |
HOOKIPA Pharma
HOOK
|
82.5 M | - | -6.92 % | $ 79.4 M | USA |
 |
Intercept Pharmaceuticals
ICPT
|
554 M | - | - | $ 643 M | USA |
 |
IGM Biosciences
IGMS
|
266 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
31.3 M | - | - | $ 13.1 M | Canada |
 |
Intra-Cellular Therapies
ITCI
|
1.37 B | - | - | $ 13.6 B | USA |
 |
Kinnate Biopharma
KNTE
|
174 M | - | - | $ 123 M | USA |
 |
Chinook Therapeutics
KDNY
|
574 M | - | - | $ 2.6 B | USA |
 |
Kaleido Biosciences
KLDO
|
50.1 M | - | -3.69 % | $ 12.4 M | USA |
 |
Kronos Bio
KRON
|
124 M | - | 1.49 % | $ 50.8 M | USA |
 |
Karuna Therapeutics
KRTX
|
1.34 B | - | - | $ 12.2 B | USA |
 |
Landos Biopharma
LABP
|
38 M | - | 0.58 % | $ 144 M | USA |
 |
La Jolla Pharmaceutical Company
LJPC
|
101 M | - | - | $ 154 M | USA |
 |
LogicBio Therapeutics
LOGC
|
62.8 M | - | - | $ 229 M | USA |
 |
Lumos Pharma
LUMO
|
40.6 M | - | - | $ 35.3 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
19.2 M | - | - | $ 216 M | USA |
 |
Stealth BioTherapeutics Corp
MITO
|
50.2 M | - | - | $ 23.9 M | USA |
 |
NexImmune
NEXI
|
8.59 M | - | 70.13 % | $ 4.12 M | USA |
 |
9 Meters Biopharma
NMTR
|
33.1 M | - | -42.97 % | $ 1.05 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
18.8 M | - | -37.48 % | $ 476 K | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
654 K | - | -19.68 % | $ 18.4 M | Canada |
 |
ObsEva SA
OBSV
|
65.4 M | - | -15.52 % | $ 10.5 M | Schweiz |
 |
Oncorus
ONCR
|
146 M | - | -8.54 % | $ 3.19 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
21.9 M | - | 31.87 % | $ 1.61 M | USA |
 |
Oncternal Therapeutics
ONCT
|
36.7 M | - | -24.12 % | $ 1.56 M | USA |
 |
Opiant Pharmaceuticals
OPNT
|
70.4 M | - | - | $ 109 M | USA |
 |
Orchard Therapeutics plc
ORTX
|
219 M | - | 1.02 % | $ 90.8 M | Britain |